Abstract
Nonnucleoside reverse transcriptase inhibitors (NNRTI) are a group of small hydrophobic compounds with diverse structures that specifically inhibit HIV-1 reverse transcriptase (RT). NNRTIs interact with HIV-1 RT by binding to a single site on the p66 subunit of the p66 / p51 heterodimeric enzyme, termed the NNRTI-binding pocket (NNRTI-BP). This binding interaction results in both short-range and long-range distortions of RT structure. In this article, we review the structural, computational and experimental evidence of the NNRTI-induced conformational changes in HIV-1 RT and relate them to the mechanism by which these compounds inhibit HIV-1 reverse transcription.
Keywords: hiv-1 reverse transcriptase, nonnucleoside reverse transcriptase inhibitor, dna polymerase, ribonuclease h
Current HIV Research
Title: Conformational Changes in HIV-1 Reverse Transcriptase Induced by Nonnucleoside Reverse Transcriptase Inhibitor Binding
Volume: 2 Issue: 4
Author(s): Nicolas Sluis-Cremer, N. Alpay Temiz and Ivet Bahar
Affiliation:
Keywords: hiv-1 reverse transcriptase, nonnucleoside reverse transcriptase inhibitor, dna polymerase, ribonuclease h
Abstract: Nonnucleoside reverse transcriptase inhibitors (NNRTI) are a group of small hydrophobic compounds with diverse structures that specifically inhibit HIV-1 reverse transcriptase (RT). NNRTIs interact with HIV-1 RT by binding to a single site on the p66 subunit of the p66 / p51 heterodimeric enzyme, termed the NNRTI-binding pocket (NNRTI-BP). This binding interaction results in both short-range and long-range distortions of RT structure. In this article, we review the structural, computational and experimental evidence of the NNRTI-induced conformational changes in HIV-1 RT and relate them to the mechanism by which these compounds inhibit HIV-1 reverse transcription.
Export Options
About this article
Cite this article as:
Sluis-Cremer Nicolas, Temiz Alpay N. and Bahar Ivet, Conformational Changes in HIV-1 Reverse Transcriptase Induced by Nonnucleoside Reverse Transcriptase Inhibitor Binding, Current HIV Research 2004; 2 (4) . https://dx.doi.org/10.2174/1570162043351093
DOI https://dx.doi.org/10.2174/1570162043351093 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Up-regulation of DMN Connectivity in Mild Cognitive Impairment Via Network-based Cognitive Training
Current Alzheimer Research Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design Role of Flavonoids in Neurodegenerative Diseases: Limitations and Future Perspectives
Current Topics in Medicinal Chemistry Immunoregulatory Impact of Food Antioxidants
Current Pharmaceutical Design Assessment of Adolescent Personality Disorders Through the Interview of Personality Organization Processes in Adolescence (IPOP-A): Clinical and Theoretical Implications
Adolescent Psychiatry The Role of Different Aspects of Impulsivity as Independent Risk Factors for Substance Use Disorders in Patients with ADHD: A Review
Current Drug Abuse Reviews Impact of Nutrition Transition and Resulting Morbidities on Economic and Human Development
Current Diabetes Reviews Amantadine, Apomorphine and Zolpidem in the Treatment of Disorders of Consciousness
Current Pharmaceutical Design Review of Evidence-Based Psychotherapies for Pediatric Mood and Anxiety Disorders
Current Psychiatry Reviews Restless Leg Syndrome Associated with Olanzapine: A Case Series
Current Drug Safety The Cardiac Microvasculature in Hypertension, Cardiac Hypertrophy and Diastolic Heart Failure
Current Vascular Pharmacology An Overview of Olive Oil Biomolecules
Current Biotechnology Pathophysiology of NASH: Perspectives for a Targeted Treatment
Current Pharmaceutical Design Plasma Indoleamine-2,3-Dioxygenase (IDO) is Increased in Drug-Naï ve Major Depressed Patients and Treatment with Sertraline and Ketoprofen Normalizes IDO in Association with Pro-Inflammatory and Immune- Regulatory Cytokines
CNS & Neurological Disorders - Drug Targets Editorial [Hot topic: New Therapeutic Strategies for Treatment of Neurodegenerative Diseases (Executive Editor: Aleksey G. Kazantsev)]
Current Pharmaceutical Design Editorial [Hot Topic: Pharmaceutical and Cellular Strategies of Recent Advances in Immunotherapy (Executive Editors: George Tuszynski and Mahesh Sharma)]
Current Pharmaceutical Design Molecular and Biochemical Features of the Mitochondrial Enzyme Ornithine Transcarbamylase: A Possible New Role as a Signaling Factor
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Neuropharmacology The Role of Omega-3 Polyunsaturated Fatty Acids Supplementation in Childhood: A Review
Recent Patents on Cardiovascular Drug Discovery Sepsis in the Central Nervous System and Antioxidant Strategies with Nacetylcysteine, Vitamins and Statins
Current Neurovascular Research